Palobiofarma key facts
- Developer of adenosine receptor modulators designed to advance treatments for orphan and neurological diseases.
- Palobiofarma’s last known valuation is $79.3M.
- It has raised $21.1M; the latest was Later Stage VC ($7.7M) in May 2024.
- Notable investors include European Union, INNVIERTE SICC, Inveready Asset Management, Sociedad de Desarrollo de Navarra, Agencia de Innovación — 15 tracked in total.
- Status: Privately Held (backing).
Who backs Palobiofarma
15+- ·The complete investor list: 15 names
- ·Watch Palobiofarma: the Monday email on marks, rounds and moves
Palobiofarma funding rounds
No funding rounds for Palobiofarma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Palobiofarma valuation
Palobiofarma's last known valuation is $79.3 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
Palobiofarma investors
15 investors are on record for Palobiofarma, including European Union, INNVIERTE SICC, Inveready Asset Management and Sociedad de Desarrollo de Navarra.
About Palobiofarma
Developer of adenosine receptor modulators designed to advance treatments for orphan and neurological diseases. The company offers virtual drug design, medicinal chemistry, in-vitro pharmacology expertise, and compound characterization capabilities, enabling biopharma researchers and healthcare providers to access targeted therapeutics with improved clinical potential.
- Sector
- Healthcare
- HQ
- Barcelona, Spain
- Founded
- 2005
- Employees
- 20
- Website
- palobiofarma.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Palobiofarma’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.